Clinical Research Directory

Inclusion Criteria * Adult patients diagnosed with advanced-stage lung cancer who are currently receiving palliative care only. * Presence of chronic cancer-related chest pain lasting longer than 1 month, localized to the thoracic region due to chest wall invasion, pleural involvement, or bone metastases. * Performance status ≤ 3 according to the Eastern Cooperative Oncology Group (ECOG), allowing placement of a subcutaneous port and maintenance of local anesthetic administration. * Inadequate pain control with conventional analgesic therapies or clinical indication for the addition of regional analgesia. * Ability to understand the study procedures and provide written informed consent after receiving a full explanation of the intervention. Exclusion Criteria: * Chest pain with radiation to the upper extremities, neck, or shoulder, suggestive of non-localized thoracic pain. * Severe hepatic or renal dysfunction, or severe heart failure (New York Heart Association class III-IV). * Local infection at the injection or port placement site, or uncontrolled systemic infection. * Severe cachexia or insufficient subcutaneous tissue that does not allow safe coverage of the subcutaneous port. * Known allergy to amide-type local anesthetics or other contraindications to regional anesthesia. * Severe cognitive impairment, altered consciousness, or inability to cooperate with post-intervention monitoring. * Lack of adequate caregiver support for home-based follow-up after discharge or inability to coordinate follow-up with local healthcare facilities. * Severe coagulation disorders, defined as: * International normalized ratio (INR) \> 1.5 * Activated partial thromboplastin time (aPTT) \> 40 seconds * Fibrinogen \< 1.5 g/L * Platelet count \< 50 × 10⁹/L.